This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis (INDIGO)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Shire Identifier:
First received: February 5, 2014
Last updated: February 24, 2017
Last verified: February 2017
This is an open label study in children with Progressive Familial Intrahepatic Cholestasis (PFIC) designed to evaluate the safety and efficacy of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 on the biochemical markers and pruritus associated with PFIC.

Condition Intervention Phase
Progressive Familial Intrahepatic Cholestasis (PFIC) Drug: LUM001 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label Study of the Efficacy and Long Term Safety of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Patients With Progressive Familial Intrahepatic Cholestasis

Resource links provided by NLM:

Further study details as provided by Shire:

Primary Outcome Measures:
  • Evaluate the effect of LUM001 by the mean change from baseline to Week 13 in fasting serum bile acid level [ Time Frame: Baseline to 13 weeks ]
    Exposure to study drug will be measured approximately 2-4 hours post dose and data will be summarized and listed across the treatment period by treatment group.

  • Evaluate the effect of LUM001 by the mean change from baseline to Week 13 on biochemical markers of cholestasis and liver disease [ Time Frame: Baseline to 13 weeks ]
    Alanine aminotransferase (ALT) and bilirubin (total and direct).

  • Evaluate the effect of LUM001 by the mean change from baseline to Week 13 on pruritus in pediatric subjects with PFIC as measured by Itch Reported Outcome (ItchRO). [ Time Frame: Baseline to 13 weeks ]
    Pruritus as measured by ItchRO (Observer ItchRO/patient ItchRO) change.

Secondary Outcome Measures:
  • Evaluate Long-Term Safety and Tolerability of LUM001 through 72 weeks and qualifed subjects who continue beyond 72 weeks. [ Time Frame: Approximately 124 weeks ]
    Safety and clinical laboratory evaluations and a physical exam (including collection of vital signs, height and weight measurements) will be completed at each clinic visit.

  • Assess the level of alpha-fetoprotein (AFP), a marker of hepatocellular carcinoma, by means of blood collection [ Time Frame: Approximately 124 weeks ]
    Blood samples to be collected and assessed every 24 weeks

Estimated Enrollment: 24
Study Start Date: March 2014
Estimated Study Completion Date: August 2018
Estimated Primary Completion Date: August 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LUM001
LUM001 administered orally once each day
Drug: LUM001
LUM001 oral dose


Ages Eligible for Study:   12 Months to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female subjects between the ages of 12 months and 18 years inclusive.
  2. Diagnosis of PFIC based on: (a) Intrahepatic cholestasis manifest by total serum bile acid >3x upper limit of normal for age; and, b or c: (b) Two documented mutant alleles in ATP8B1, or ABCB11; (c) Evidence of chronic liver disease
  3. GGTP <100 IU/L at screening.
  4. Females of childbearing potential must have a negative urine or serum pregnancy test during screening and a negative urine pregnancy test at the Baseline (Day 0) visit.
  5. Sexually active or potentially active males and females of child-bearing potential must be prepared to use an effective method(s) of contraception during the period of the study and 30 days following the last dose of study drug.
  6. Access to phone for scheduled calls from study site.
  7. Caregivers and children above the age of assent must have the ability to read and understand one of the following languages: English, Spanish, US Spanish, French, German or Polish.
  8. Subjects expected to have a consistent caregiver(s) for the duration of the first 13 weeks of the study.
  9. Caregivers (and age appropriate subjects) must be willing and able to use an eDiary device as required by the study, and must digitally accespt the licensing agreement.
  10. Caregivers (and age appropriate subjects) must complete at least 10 eDiary reports (morning or evening) during each of two consecutive weeks of the screening period, prior to assignment (maximum possible reports = 14 per week).

Exclusion Criteria:

  1. Chronic diarrhea requiring specific intravenous fluid or nutritional intervention for the diarrhea and/or its sequelae.
  2. Surgical disruption of the enterohepatic circulation at the time at screening. Subjects who have undergone reversal of a prior surgical procedure intended to disrupt enterohepatic circulation and who and have a permanently restored flow of bile acids from the liver to the terminal ileum may be eligible for the study upon consultation with the Sponsor Medical Monitor.
  3. Liver transplant.
  4. Decompensated cirrhosis.
  5. ALT > 15 x ULN at screening.
  6. History or presence of other liver disease.
  7. History or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs, including bile salt metabolism in the intestine (e.g., inflammatory bowel disease).
  8. Liver mass on imaging.
  9. Known diagnosis of human immunodeficiency virus (HIV) infection.
  10. Cancers except for in situ carcinoma, or cancers treated at least 5 years prior to screening with no evidence of recurrence.
  11. Any female who is pregnant or lactating or who is planning to become pregnant within 20 weeks of assignment.
  12. Any known history of alcohol or substance abuse.
  13. Administration of bile acid or lipid binding resins within 30 days prior to Baseline / Day 0 and throughout the trial.
  14. Administration of sodium phenylbutyrate within 30 days prior to Baseline / Day 0 and throughout the trial.
  15. Investigational drug, biologic, or medical device within 30 days prior to screening, or 5 half-lives of the study agent, whichever is longer.
  16. History of non-adherence to medical regimens, unreliability, mental instability or incompetence that could compromise the validity of informed consent or lead to non-adherence with the study protocol based on Investigator judgment.
  17. Any other conditions or abnormalities which, in the opinion of the Investigator or Sponsor Medical Monitor, may compromise the safety of the subject, or interfere with the subject participating in or completing the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02057718

United States, California
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
United States, Colorado
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
United States, Pennsylvania
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States, 15224
Hopital Femme Mere Enfant De Lyon
Bron, France, 69677
The Children's Memorial Health Institute
Warsaw, Poland, 04-730
United Kingdom
Birmingham Children's Hospital
Steelhouse Lane, Birmingham West Midlands, United Kingdom, B4 6NH
Leeds Teaching Hospital NHS Trust
Great George Street, Leeds, United Kingdom, LS1 3EX
Kings College Hospital
London, United Kingdom, SE5 9RS
Sponsors and Collaborators
Study Director: Shire Physician Shire
  More Information

Responsible Party: Shire Identifier: NCT02057718     History of Changes
Other Study ID Numbers: LUM001-501
2013-003833-14 ( EudraCT Number )
Study First Received: February 5, 2014
Last Updated: February 24, 2017

Additional relevant MeSH terms:
Liver Diseases
Cholestasis, Intrahepatic
Digestive System Diseases
Bile Duct Diseases
Biliary Tract Diseases processed this record on August 18, 2017